Analysts Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $21.00

OptimizeRx Corp. (NASDAQ:OPRX) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $21.00.

OPRX has been the subject of several recent analyst reports. JMP Securities raised their target price on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stephens dropped their target price on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Finally, UBS Group set a $23.00 price target on OptimizeRx in a research note on Friday, October 10th.

Institutional Trading of OptimizeRx

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its stake in OptimizeRx by 600.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx during the second quarter valued at $44,000. BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after buying an additional 2,215 shares during the last quarter. USA Financial Formulas acquired a new position in shares of OptimizeRx in the 3rd quarter valued at $131,000. Finally, Corton Capital Inc. purchased a new position in OptimizeRx in the 2nd quarter worth $138,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Price Performance

Shares of OPRX stock opened at $12.15 on Tuesday. The stock’s 50-day moving average is $13.74 and its 200 day moving average is $15.84. OptimizeRx has a 1-year low of $3.99 and a 1-year high of $22.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05. The company has a market cap of $226.48 million, a P/E ratio of 30.38 and a beta of 1.09.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.03 by $0.17. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. The business had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. Research analysts predict that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.